The Sickle Cell Disease Treatment Market is being driven by High prevalence of sickle cell disease
The Sickle Cell Disease Treatment Market is expected to grow at a CAGR of 16.2% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 3345.1 million. The sickle cell disease treatment market is experiencing a significant shift, transitioning from symptom management towards curative interventions. Traditional care has primarily focused on palliative measures like pain medications, blood transfusions, and hydroxyurea therapies, which alleviate complications but do not address the disease's genetic root cause. This trend is changing due to three key developments. First, the regulatory approval of gene-based therapies, such as Casgevy and Lyfgenia in 2023, represents a groundbreaking achievement. These therapies, utilizing CRISPR and lentiviral technologies, have shown over 90% reduction in severe vaso-occlusive crises in clinical trials, providing the first curative prospects for patients.
Get more information on Sickle Cell Disease Treatment Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Market Scope |
|
Report Coverage |
Details |
Page number |
215 |
Base year |
2024 |
Historic period |
2019-2023 |
Forecast period |
2025-2029 |
Growth momentum & CAGR |
Accelerate at a CAGR of 16.2% |
Market growth 2025-2029 |
USD 3345.1 million |
Market structure |
fragmentation |
YoY growth 2024-2025(%) |
14.4 |
Key countries |
US, India, Germany, China, UK, Canada, France, Japan, Brazil, and South Korea |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Sickle Cell Foundation focuses on advancing treatments for sickle cell disease through collaborations between sickle cell clinics, sickle cell specialists, social workers, and caregivers. Patient empowerment and advocacy are key, with an emphasis on improving clinical outcomes, such as survival rates, patient satisfaction, functional status, pain intensity, cognitive function, and emotional well-being. Health service utilization, hospital admissions, and emergency room visits are also crucial areas of concern. Innovative treatments like bone marrow transplants, clinical trials using lentiviral gene transfer and CRISPRCas9 therapy, and stroke management are being explored to reduce the healthcare burden and economic impact of sickle cell anemia on patients and their families. The disease's social impact is also addressed through community support and addressing the challenges of vasoocclusive crisis and pain intensity.
The Sickle Cell Disease Treatment Market encompasses businesses involved in the research and development (R&D) or production of various treatments, including gene therapy, blood transfusions, bone marrow transplant, acute chest syndrome management, chronic pain management, pain relief medications, non-opioid pain relief, and anti-inflammatory drugs. According to Technavio, the global pharmaceuticals market, which includes these treatments, is projected to expand due to several factors, such as the increasing global population aging, with the US and Europe forecasted to have nearly one-quarter of their populations aged 60 and above by 2050 and 2030, respectively. This demographic shift will drive the demand for healthcare solutions, including those for Sickle Cell Disease Treatment.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted